Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed lung cancer
• * All histologic types eligible
• * Recurrent or progressive disease after ≥ 1 prior chemotherapy regimen with or without radiotherapy
• PATIENT CHARACTERISTICS:
• ECOG performance status (PS) ≤ 2
• Karnofsky PS ≥ 60%
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Total bilirubin ≤ 1.5 mg/dL
• Creatinine ≤ 1.5 mg/dL
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No other active invasive malignancy
• No uncontrolled illness including, but not limited to:
• * Ongoing or active infection
• * Symptomatic congestive heart failure
• * Unstable angina pectoris
• * Cardiac arrhythmia
• No psychiatric illness/social situation that would limit compliance with study requirements
• No history of allergic reactions attributed to compounds of similar chemical or biologic composition to topotecan or vinorelbine ditartrate
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• At least 2 weeks since prior radiotherapy
• No prior therapy with topotecan or vinorelbine ditartrate
• No chemotherapy within the past 4 weeks (6 weeks for nitrosoureas or mitomycin C)
• Recovered from agents administered \> 4 weeks earlier
• No other concurrent investigational agents
• No concurrent palliative radiotherapy
• No other concurrent anticancer therapies or agents
• No concurrent hormones or other chemotherapy except for the following:
• * Steroids for adrenal failure
• * Hormones for nondisease-related conditions (e.g., insulin for diabetes)
• * Intermittent dexamethasone as an antiemetic